<?xml version='1.0' encoding='utf8'?>
<text id="AMALGUM_academic_msc" title="Substantial Overview on Mesenchymal Stem Cell Biological and Physical Properties as an Opportunity in Translational Medicine" shortTitle="msc" author="Heba Abdelrazik, Emanuele Giordano, Giovanni Barbanti Brodano, Cristiana Griffoni, Elena De Falco, Alessandra Pelagalli" type="academic" dateCollected="2019-11-03" sourceURL="https://www.mdpi.com/1422-0067/20/21/5386/htm" speakerList="none" speakerCount="0">
<head>
<s type="frag">
6.	LS	6.
Challenges	NNS	challenge
in	IN	in
MSC	NNP	MSC
Translation	NN	Translation
into	IN	into
Clinical	NNP	Clinical
Practice	NN	practice
:	:	:
</s>
<s type="frag">
The	DT	the
Bone	NNP	Bone
Disease	NNP	Disease
Framework	NNP	Framework
</s>
</head>
<p>
<s type="decl">
Other	JJ	other
interesting	JJ	interesting
aspects	NNS	aspect
and	CC	and
new	JJ	new
perspectives	NNS	perspective
in	IN	in
the	DT	the
field	NN	field
of	IN	of
tissue	NN	tissue
regeneration	NN	regeneration
and	CC	and
applicative	JJ	applicative
use	NN	use
of	IN	of
MSC	NNP	MSC
are	VBP	be
strictly	RB	strictly
related	JJ	related
to	IN	to
their	PRP$	their
potential	NN	potential
to	TO	to
tackle	VB	tackle
the	DT	the
increase	NN	increase
in	IN	in
bone	NN	bone
diseases	NNS	disease
related	VBN	relate
with	IN	with
the	DT	the
extended	VBN	extend
life	NN	life
expectancy	NN	expectancy
.	.	.
</s>
<s type="decl">
Indeed	RB	indeed
,	,	,
in	IN	in
many	JJ	many
countries	NNS	country
bone	NN	bone
diseases	NNS	disease
are	VBP	be
becoming	VBG	become
a	DT	a
relevant	JJ	relevant
cause	NN	cause
of	IN	of
disability	NN	disability
,	,	,
even	RB	even
if	IN	if
they	PRP	they
are	VBP	be
acute	JJ	acute
,	,	,
such	JJ	such
as	IN	as
fractures	NNS	fracture
,	,	,
or	CC	or
chronic	JJ	chronic
,	,	,
such	JJ	such
as	IN	as
osteoporosis	NN	osteoporosis
and	CC	and
tumours	NNS	tumour
.	.	.
</s>
<s type="decl">
In	IN	in
any	DT	any
case	NN	case
these	DT	this
pathologies	NNS	pathology
require	VBP	require
treatments	NNS	treatment
to	TO	to
enhance	VB	enhance
the	DT	the
healing	NN	healing
and	CC	and
regenerative	JJ	regenerative
capacity	NN	capacity
of	IN	of
bone	NN	bone
tissue	NN	tissue
.	.	.
</s>
<s type="decl">
The	DT	the
common	JJ	common
therapeutic	JJ	therapeutic
strategies	NNS	strategy
based	VBN	base
on	IN	on
bone	NN	bone
grafting	NN	grafting
(	-LRB-	(
autografts	NNS	autograft
or	CC	or
allografts	NNS	allograft
)	-RRB-	)
show	VBP	show
some	DT	some
disadvantages	NNS	disadvantage
.	.	.
</s>
<s type="decl">
Autografts	NNS	autograft
are	VBP	be
limited	VBN	limit
by	IN	by
the	DT	the
bone	NN	bone
volume	NN	volume
that	WDT	that
can	MD	can
be	VB	be
harvested	VBN	harvest
from	IN	from
the	DT	the
iliac	NN	iliac
crest	NN	crest
and	CC	and
present	JJ	present
surgical	JJ	surgical
risks	NNS	risk
such	JJ	such
as	IN	as
bleeding	NN	bleeding
,	,	,
inflammation	NN	inflammation
,	,	,
infection	NN	infection
,	,	,
chronic	JJ	chronic
pain	NN	pain
,	,	,
damage	NN	damage
at	IN	at
the	DT	the
donor	NN	donor
site	NN	site
and	CC	and
morbidity	NN	morbidity
.	.	.
</s>
<s type="decl">
Allografts	NNS	allograft
also	RB	also
have	VBP	have
some	DT	some
limitations	NNS	limitation
,	,	,
such	JJ	such
as	IN	as
the	DT	the
lack	NN	lack
of	IN	of
donors	NNS	donor
,	,	,
high	JJ	high
costs	NNS	cost
,	,	,
the	DT	the
need	NN	need
for	IN	for
sterilization	NN	sterilization
and	CC	and
the	DT	the
risk	NN	risk
of	IN	of
infectious	JJ	infectious
agent	NN	agent
transmission	NN	transmission
or	CC	or
immune	JJ	immune
mediated	VBN	mediate
tissue	NN	tissue
rejection	NN	rejection
.	.	.
</s>
</p>
<p>
<s type="decl">
These	DT	this
limitations	NNS	limitation
and	CC	and
disadvantages	NNS	disadvantage
associated	VBN	associate
with	IN	with
auto-	JJ	auto-
and	CC	and
allograft	NN	allograft
approaches	NNS	approach
indicate	VBP	indicate
a	DT	a
clinical	JJ	clinical
need	NN	need
for	IN	for
alternative	JJ	alternative
therapeutic	JJ	therapeutic
strategies	NNS	strategy
aimed	VBN	aim
at	IN	at
bone	NN	bone
healing	NN	healing
and	CC	and
regeneration	NN	regeneration
.	.	.
</s>
<s type="decl">
Thus	RB	thus
,	,	,
new	JJ	new
biomaterials	NNS	biomaterial
and	CC	and
scaffolds	NNS	scaffold
,	,	,
in	IN	in
association	NN	association
with	IN	with
MSC	NNP	MSC
and	CC	and
growth	NN	growth
factors	NNS	factor
,	,	,
having	VBG	have
requirements	NNS	requirement
of	IN	of
biocompatibility	NN	biocompatibility
,	,	,
osteoinductive	JJ	osteoinductive
and	CC	and
osteoconductive	JJ	osteoconductive
properties	NNS	property
,	,	,
are	VBP	be
investigated	VBN	investigate
to	TO	to
improve	VB	improve
bone	NN	bone
repair	NN	repair
.	.	.
</s>
<s type="decl">
The	DT	the
use	NN	use
of	IN	of
MSC	NNP	MSC
is	VBZ	be
attractive	JJ	attractive
since	IN	since
they	PRP	they
can	MD	can
be	VB	be
harvested	VBN	harvest
from	IN	from
the	DT	the
host	NN	host
with	IN	with
minimal	JJ	minimal
morbidity	NN	morbidity
,	,	,
they	PRP	they
can	MD	can
be	VB	be
modified	VBN	modify
to	TO	to
secrete	VB	secrete
osteoinductive	JJ	osteoinductive
factors	NNS	factor
and	CC	and
implanted	VBN	implant
on	IN	on
an	DT	a
osteoconductive	JJ	osteoconductive
scaffold	NN	scaffold
,	,	,
to	TO	to
obtain	VB	obtain
the	DT	the
three	CD	3
key	JJ	key
components	NNS	component
leading	VBG	lead
to	IN	to
osteogenesis	NN	osteogenesis
.	.	.
</s>
</p>
<p>
<s type="decl">
hMSC	NNS	hMSC
have	VBP	have
been	VBN	be
found	VBN	find
in	IN	in
several	JJ	several
adult	JJ	adult
tissues	NNS	tissue
,	,	,
including	VBG	include
the	DT	the
synovial	JJ	synovial
membrane	NN	membrane
,	,	,
the	DT	the
adipose	NN	adipose
tissue	NN	tissue
,	,	,
the	DT	the
dental	JJ	dental
pulp	NN	pulp
tissue	NN	tissue
,	,	,
or	CC	or
in	IN	in
perinatal	JJ	perinatal
tissues	NNS	tissue
(	-LRB-	(
umbilical	JJ	umbilical
cord	NN	cord
blood	NN	blood
and	CC	and
umbilical	JJ	umbilical
cord	NN	cord
tissue	NN	tissue
)	-RRB-	)
.	.	.
</s>
<s type="decl">
All	PDT	all
these	DT	this
cells	NNS	cell
are	VBP	be
suited	VBN	suit
to	IN	to
therapeutic	JJ	therapeutic
applications	NNS	application
for	IN	for
bone	NN	bone
regeneration	NN	regeneration
,	,	,
by	IN	by
means	NNS	means
of	IN	of
two	CD	2
different	JJ	different
ways	NNS	way
of	IN	of
autologous	JJ	autologous
cells	NNS	cell
transplantation	NN	transplantation
:	:	:
(	-LRB-	(
1	CD	1
)	-RRB-	)
cell	NN	cell
therapies	NNS	therapy
without	IN	without
expansion	NN	expansion
in	IN	in
culture	NN	culture
(	-LRB-	(
one-step	JJ	one-step
procedure	NN	procedure
)	-RRB-	)
and	CC	and
(	-LRB-	(
2	CD	2
)	-RRB-	)
cell	NN	cell
therapies	NNS	therapy
with	IN	with
ex	NN	ex
vivo	NN	vivo
expansion	NN	expansion
.	.	.
</s>
<s type="decl">
In	IN	in
the	DT	the
first	JJ	first
case	NN	case
,	,	,
cells	NNS	cell
are	VBP	be
harvested	VBN	harvest
during	IN	during
surgery	NN	surgery
.	.	.
</s>
<s type="decl">
In	IN	in
<date when="2010">
2010	CD	2010
</date>
,	,	,
Jagër	NNP	Jagër
et	FW	et
al.	FW	al.
,	,	,
successfully	RB	successfully
treated	VBD	treat
more	RBR	more
than	IN	than
100	CD	100
patients	NNS	patient
with	IN	with
local	JJ	local
bone	NN	bone
healing	NN	healing
disorders	NNS	disorder
using	VBG	use
a	DT	a
biomaterial	JJ	biomaterial
composite	NN	composite
in	IN	in
association	NN	association
with	IN	with
BM	NNP	BM
aspiration	NN	aspiration
concentrate	NN	concentrate
.	.	.
</s>
<s type="decl">
They	PRP	they
observed	VBD	observe
that	IN	that
the	DT	the
use	NN	use
of	IN	of
BM	NNP	BM
concentrate	NN	concentrate
reduced	VBD	reduce
the	DT	the
harvest	NN	harvest
of	IN	of
autogenous	JJ	autogenous
bone	NN	bone
by	IN	by
50	CD	50
%	NN	%
without	IN	without
negative	JJ	negative
effects	NNS	effect
on	IN	on
bone	NN	bone
healing	NN	healing
.	.	.
</s>
<s type="decl">
The	DT	the
second	JJ	second
clinical	JJ	clinical
application	NN	application
of	IN	of
MSC	NNP	MSC
includes	VBZ	include
the	DT	the
autologous	JJ	autologous
cell	NN	cell
transplantation	NN	transplantation
after	IN	after
ex-vivo	JJ	ex-vivo
expansion	NN	expansion
.	.	.
</s>
<s type="decl">
In	IN	in
<date when="2007">
2007	CD	2007
</date>
,	,	,
Nöth	NNP	Nöth
et	FW	et
al.	FW	al.
,	,	,
used	VBD	use
a	DT	a
cell	NN	cell
population	NN	population
from	IN	from
BM	NNP	BM
aspirate	NN	aspirate
cultured	VBN	culture
over	IN	over
12	CD	12
days	NNS	day
under	IN	under
GMP	NNP	GMP
conditions	NNS	condition
and	CC	and
transplanted	VBD	transplant
them	PRP	they
autologously	RB	autologously
with	IN	with
a	DT	a
tricalcium	NN	tricalcium
phosphate	NN	phosphate
biomaterial	NN	biomaterial
for	IN	for
the	DT	the
treatment	NN	treatment
of	IN	of
femoral	JJ	femoral
head	NN	head
necrosis	NN	necrosis
.	.	.
</s>
<s type="decl">
The	DT	the
main	JJ	main
limitations	NNS	limitation
for	IN	for
clinical	JJ	clinical
application	NN	application
are	VBP	be
the	DT	the
sterility	NN	sterility
technique	NN	technique
,	,	,
long	JJ	long
culture	NN	culture
time	NN	time
,	,	,
high	JJ	high
cost	NN	cost
,	,	,
and	CC	and
the	DT	the
mixture	NN	mixture
of	IN	of
human	JJ	human
cell	NN	cell
culture	NN	culture
medium	NN	medium
with	IN	with
fetal	JJ	fetal
bovine	NN	bovine
serum	NN	serum
.	.	.
</s>
<s type="decl">
Thus	RB	thus
,	,	,
recently	RB	recently
,	,	,
orthopedic	JJ	orthopedic
researchers	NNS	researcher
focused	VBD	focus
their	PRP$	their
attention	NN	attention
on	IN	on
the	DT	the
clinical	JJ	clinical
use	NN	use
of	IN	of
BM	NNP	BM
aspirate	NN	aspirate
(	-LRB-	(
BMA	NNP	BMA
)	-RRB-	)
and	CC	and
BM	NNP	BM
concentrate	NN	concentrate
(	-LRB-	(
BMC	NNP	BMC
)	-RRB-	)
for	IN	for
musculoskeletal	JJ	musculoskeletal
regeneration	NN	regeneration
with	IN	with
a	DT	a
“	``	''
one-step	JJ	one-step
”	''	''
procedure	NN	procedure
,	,	,
avoiding	VBG	avoid
the	DT	the
need	NN	need
of	IN	of
additional	JJ	additional
laboratory	NN	laboratory
stages	NNS	stage
and	CC	and
GMP	NNP	GMP
facility	NN	facility
,	,	,
thus	RB	thus
reducing	VBG	reduce
costs	NNS	cost
and	CC	and
risks	NNS	risk
.	.	.
</s>
</p>
<p>
<s type="decl">
Bone	NN	bone
marrow	NN	marrow
contains	VBZ	contain
MSC	NNP	MSC
,	,	,
hematopoietic	JJ	hematopoietic
stem	NN	stem
cells	NNS	cell
,	,	,
endothelial	JJ	endothelial
progenitor	NN	progenitor
cells	NNS	cell
,	,	,
other	JJ	other
progenitor	NN	progenitor
cells	NNS	cell
and	CC	and
growth	NN	growth
factors	NNS	factor
,	,	,
including	VBG	include
bone	NN	bone
morphogenetic	NN	morphogenetic
proteins	NNS	protein
(	-LRB-	(
BMP	NNP	BMP
)	-RRB-	)
,	,	,
platelet-derived	JJ	platelet-derived
growth	NN	growth
factor	NN	factor
(	-LRB-	(
PDGF	NNP	PDGF
)	-RRB-	)
,	,	,
transforming	VBG	transform
growth	NN	growth
factor-β	NN	factor-β
(	-LRB-	(
TGF-β	NNP	TGF-β
)	-RRB-	)
,	,	,
vascular	JJ	vascular
endothelial	NN	endothelial
growth	NN	growth
factor	NN	factor
(	-LRB-	(
VEGF	NNP	VEGF
)	-RRB-	)
,	,	,
interleukin-8	NN	interleukin-8
(	-LRB-	(
IL-8	NNP	IL-8
)	-RRB-	)
,	,	,
and	CC	and
IL-1	NNP	IL-1
receptor	NN	receptor
antagonist	NN	antagonist
.	.	.
</s>
<s type="decl">
It	PRP	it
has	VBZ	have
been	VBN	be
identified	VBN	identify
as	IN	as
an	DT	a
excellent	JJ	excellent
source	NN	source
of	IN	of
cells	NNS	cell
and	CC	and
growth	NN	growth
factors	NNS	factor
and	CC	and
it	PRP	it
has	VBZ	have
been	VBN	be
used	VBN	use
with	IN	with
success	NN	success
for	IN	for
bone	NN	bone
,	,	,
cartilage	NN	cartilage
and	CC	and
soft	JJ	soft
tissue	NN	tissue
healing	NN	healing
.	.	.
</s>
</p>
<p>
<s type="decl">
We	PRP	we
focused	VBD	focus
our	PRP$	our
attention	NN	attention
on	IN	on
the	DT	the
use	NN	use
of	IN	of
BM-derived	NNP	BM-derived
MSC	NNP	MSC
in	IN	in
spinal	JJ	spinal
fusion	NN	fusion
surgical	JJ	surgical
procedures	NNS	procedure
,	,	,
which	WDT	which
is	VBZ	be
the	DT	the
most	RBS	most
definitive	JJ	definitive
treatment	NN	treatment
performed	VBN	perform
to	TO	to
restore	VB	restore
the	DT	the
structural	JJ	structural
stability	NN	stability
of	IN	of
the	DT	the
spinal	JJ	spinal
column	NN	column
in	IN	in
degenerative	JJ	degenerative
and	CC	and
oncological	JJ	oncological
spine	NN	spine
diseases	NNS	disease
.	.	.
</s>
<s type="decl">
Currently	RB	currently
,	,	,
the	DT	the
gold	NN	gold
standard	JJ	standard
stimulus	NN	stimulus
to	TO	to
achieve	VB	achieve
spinal	JJ	spinal
fusion	NN	fusion
is	VBZ	be
autologous	JJ	autologous
bone	NN	bone
(	-LRB-	(
autograft	NN	autograft
)	-RRB-	)
,	,	,
which	WDT	which
is	VBZ	be
commonly	RB	commonly
harvested	VBN	harvest
from	IN	from
the	DT	the
iliac	NN	iliac
crest	NN	crest
or	CC	or
obtained	VBN	obtain
from	IN	from
the	DT	the
surgical	JJ	surgical
site	NN	site
(	-LRB-	(
local	JJ	local
bone	NN	bone
)	-RRB-	)
.	.	.
</s>
<s type="decl">
As	IN	as
autologous	JJ	autologous
bone	NN	bone
possesses	VBZ	possess
osteogenic	JJ	osteogenic
,	,	,
osteoinductive	JJ	osteoinductive
and	CC	and
osteoconductive	JJ	osteoconductive
abilities	NNS	ability
;	:	;
the	DT	the
success	NN	success
rate	NN	rate
of	IN	of
spinal	JJ	spinal
fusion	NN	fusion
with	IN	with
autograft	NN	autograft
is	VBZ	be
high	JJ	high
(	-LRB-	(
up	IN	up
to	IN	to
95	CD	95
%	NN	%
)	-RRB-	)
.	.	.
</s>
<s type="decl">
However	RB	however
,	,	,
autograft	JJ	autograft
material	NN	material
is	VBZ	be
limited	VBN	limit
in	IN	in
quantity	NN	quantity
and	CC	and
its	PRP$	its
quality	NN	quality
varies	VBZ	vary
depending	VBG	depend
on	IN	on
the	DT	the
patient	NN	patient
.	.	.
</s>
<s type="decl">
Moreover	RB	moreover
,	,	,
significant	JJ	significant
morbidity	NN	morbidity
is	VBZ	be
associated	VBN	associate
with	IN	with
bone	NN	bone
harvesting	NN	harvesting
,	,	,
as	IN	as
previously	RB	previously
described	VBN	describe
.	.	.
</s>
<s type="decl">
Between	IN	between
many	JJ	many
alternatives	NNS	alternative
proposed	VBN	propose
to	TO	to
achieve	VB	achieve
spinal	JJ	spinal
fusion	NN	fusion
,	,	,
MSC	NNP	MSC
are	VBP	be
interesting	JJ	interesting
because	IN	because
they	PRP	they
can	MD	can
provide	VB	provide
osteogenic	JJ	osteogenic
properties	NNS	property
allowing	VBG	allow
bone	NN	bone
regeneration	NN	regeneration
.	.	.
</s>
</p>
<p>
<s type="decl">
We	PRP	we
recently	RB	recently
published	VBD	publish
a	DT	a
descriptive	JJ	descriptive
systematic	JJ	systematic
literature	NN	literature
review	NN	review
in	IN	in
order	NN	order
to	TO	to
understand	VB	understand
if	IN	if
the	DT	the
use	NN	use
of	IN	of
MSC	NNP	MSC
may	MD	may
represent	VB	represent
a	DT	a
valid	JJ	valid
strategy	NN	strategy
to	TO	to
facilitate	VB	facilitate
and	CC	and
accelerate	VB	accelerate
bone	NN	bone
regeneration	NN	regeneration
and	CC	and
fusion	NN	fusion
during	IN	during
spine	NN	spine
surgery	NN	surgery
.	.	.
</s>
<s type="decl">
In	IN	in
this	DT	this
review	NN	review
we	PRP	we
selected	VBD	select
and	CC	and
analyzed	VBD	analyze
50	CD	50
relevant	JJ	relevant
papers	NNS	paper
,	,	,
stratified	VBN	stratify
according	VBG	accord
to	IN	to
preclinical	JJ	preclinical
studies	NNS	study
and	CC	and
clinical	JJ	clinical
trials	NNS	trial
.	.	.
</s>
<s type="decl">
Preclinical	JJ	Preclinical
published	VBN	publish
data	NNS	datum
showed	VBD	show
that	IN	that
MSC	NNP	MSC
have	VBP	have
the	DT	the
potential	NN	potential
to	TO	to
achieve	VB	achieve
,	,	,
facilitate	VB	facilitate
and	CC	and
accelerate	VB	accelerate
spinal	JJ	spinal
fusion	NN	fusion
.	.	.
</s>
<s type="decl">
However	RB	however
,	,	,
preclinical	JJ	preclinical
studies	NNS	study
on	IN	on
animal	NN	animal
models	NNS	model
indicated	VBD	indicate
that	IN	that
some	DT	some
barriers	NNS	barrier
remain	VBP	remain
prior	JJ	prior
to	IN	to
this	DT	this
therapy	NN	therapy
translation	NN	translation
into	IN	into
the	DT	the
clinical	JJ	clinical
application	NN	application
.	.	.
</s>
</p>
<p>
<s type="decl">
So	RB	so
far	RB	far
,	,	,
few	JJ	few
published	VBN	publish
clinical	JJ	clinical
studies	NNS	study
employ	VBP	employ
stem	NN	stem
cells	NNS	cell
for	IN	for
spinal	JJ	spinal
fusion	NN	fusion
.	.	.
</s>
<s type="decl">
Most	JJS	most
of	IN	of
them	PRP	they
used	VBD	use
concentrated	VBN	concentrate
autologous	JJ	autologous
BM	NN	BM
as	IN	as
primary	JJ	primary
source	NN	source
of	IN	of
stem	NN	stem
cells	NNS	cell
and	CC	and
they	PRP	they
showed	VBD	show
fusion	NN	fusion
results	NNS	result
ranging	VBG	range
from	IN	from
87	CD	87
%	NN	%
to	IN	to
92.3	CD	92.3
%	NN	%
in	IN	in
a	DT	a
total	NN	total
of	IN	of
297	CD	297
patients	NNS	patient
.	.	.
</s>
</p>
</text>